Clinical Trial Update: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TQB3616 capsules in combination with abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• TQB3616

Snippet

Sponsor: West China Hospital | Conditions: Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination | Phase 2 | Status: UNKNOWN